Epidermal Growth Factor Receptor-Targeted Therapies



The epidermal growth factor receptor (EGFR) has been implicated in the progression and maintenance of various solid tumors. Efforts in understanding EGFR biology and related signaling cascades have lead to the development of anti-EGFR agents. The two main approaches of inhibition that have been ­studied most extensively are monoclonal antibodies and tyrosine kinase inhibitors. Despite clear evidence of antitumor activity in preclinical models, only a subset of cancer patients show clinical responses to EGFR inhibitors. Additionally, a majority of patients who demonstrate an initial response become refractory to continued therapy. Possible mechanisms of resistance to anti-EGFR therapy include EGFR overexpression, redundant parallel growth factor receptors, ErbB family heterodimerization, EGFR mutations, the presence of nuclear EGFR, and constitutive activation of downstream signaling mediators. Understanding the molecular mechanisms of resistance is critical in the development of combination therapies to target resistance pathways and improve clinical outcomes. Furthermore, idenepsication of biomarkers that indicate sensitivity or resistance to anti-EGFR therapy will enable the selection of patients who are more likely to benefit from EGFR-targeted therapy.

The epidermal growth factor receptor (EGFR) tyrosine kinase plays an important role in the progression of many human cancers, and molecular inhibitors that target EGFR have been extensively investigated for anti-cancer therapy. Anti-EGFR agents have shown promising activity in clinical trials and are now Food and Drug Administration (FDA)-approved for use in selected groups of cancer patients. However, most patients ultimately develop resistance to these agents. In this chapter, we will discuss the therapeutic potential of targeting EGFR, the effects of using EGFR inhibitors, and possible mechanisms of resistance to EGFR inhibitors.


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Expression Epidermal Growth Factor Receptor Inhibition Epidermal Growth Factor Receptor Gene Epidermal Growth Factor Receptor Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by the American Cancer Society, P50CA097190, R01CA77308, and R01CA098372, to JRG.


  1. Abidoye OO, Cohen EE, Wong SJ et al. (2006) A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24(18S):5568 (meeting abstracts)Google Scholar
  2. Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab ­efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRefGoogle Scholar
  3. Amador ML, Oppenheimer D, Perea S et al. (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139–9143PubMedCrossRefGoogle Scholar
  4. Banerjee A, Rothman P (1998) IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling. J Immunol 161:4611–4617PubMedGoogle Scholar
  5. Baselga J, Pfister D, Cooper MR et al. (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904–914PubMedGoogle Scholar
  6. Baselga J, Rischin D, Ranson M et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292–4302PubMedCrossRefGoogle Scholar
  7. Baselga J, Trigo JM, Bourhis J et al. (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577PubMedCrossRefGoogle Scholar
  8. Batra SK, Castelino-Prabhu S, Wikstrand CJ et al. (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6:1251–1259PubMedGoogle Scholar
  9. Baulida J, Kraus MH, Alimandi M et al. (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251–5257PubMedCrossRefGoogle Scholar
  10. Bei R, Budillon A, Masuelli L et al. (2004) Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 204:317–325PubMedCrossRefGoogle Scholar
  11. Bianco R, Shin I, Ritter CA et al. (2003) Loss of PTEN//MMAC1//TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822PubMedCrossRefGoogle Scholar
  12. Bianco R, Rosa R, Damiano V et al. (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14:5069–5080PubMedCrossRefGoogle Scholar
  13. Bokemeyer C, Bondarenko I, Hartmann JT et al. (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 26(15S):4000 (meeting abstracts)Google Scholar
  14. Bonner JA, Harari PM, Giralt J et al. (2006) Radiotherapy plus cetuximab for squamous-cell ­carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRefGoogle Scholar
  15. Burtness B, Goldwasser MA, Flood W et al. (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 23:8646–8654PubMedCrossRefGoogle Scholar
  16. Cappuzzo F, Hirsch FR, Rossi E et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRefGoogle Scholar
  17. Cavalot A, Martone T, Roggero N et al. (2007) Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29:655–664PubMedCrossRefGoogle Scholar
  18. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200–207PubMedGoogle Scholar
  19. Chan AT, Hsu MM, Goh BC et al. (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23:3568–3576PubMedCrossRefGoogle Scholar
  20. Chung CH, Ely K, McGavran L et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176PubMedCrossRefGoogle Scholar
  21. Cohen EE, Rosen F, Stadler WM et al. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987PubMedCrossRefGoogle Scholar
  22. Cohen EE, Kane MA, List MA et al. (2005) Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418–8424PubMedCrossRefGoogle Scholar
  23. Cohen EE, Davis DW, Karrison TG et al. (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10:247–257PubMedCrossRefGoogle Scholar
  24. Costa DB, Nguyen KS, Cho BC et al. (2008) Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14:7060–7067PubMedCrossRefGoogle Scholar
  25. Curran D, Giralt J, Harari PM et al. (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197PubMedCrossRefGoogle Scholar
  26. Daaka Y (2004) G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004:re2PubMedCrossRefGoogle Scholar
  27. Damstrup L, Wandahl Pedersen M, Bastholm L et al. (2002) Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 97:7–14PubMedCrossRefGoogle Scholar
  28. Daub H, Weiss FU, Wallasch C et al. (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557–560PubMedCrossRefGoogle Scholar
  29. Dechant M, Weisner W, Berger S et al. (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68:4998–5003PubMedCrossRefGoogle Scholar
  30. Dempke WC, Heinemann V (2009) Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45:1117–1128PubMedCrossRefGoogle Scholar
  31. Dittmann K, Mayer C, Kehlbach R et al. (2008) Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 7:69PubMedCrossRefGoogle Scholar
  32. Egloff AM, Grandis JR (2008) Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin Oncol 35:286–297PubMedCrossRefGoogle Scholar
  33. Ekstrand AJ, Longo N, Hamid ML et al. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320PubMedGoogle Scholar
  34. Ellis CA, Clark G (2000) The importance of being K-Ras. Cell Signal 12:425–434PubMedCrossRefGoogle Scholar
  35. Erjala K, Sundvall M, Junttila TT et al. (2006) Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12:4103–4111PubMedCrossRefGoogle Scholar
  36. Ferguson KM, Berger MB, Mendrola JM et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507–517PubMedCrossRefGoogle Scholar
  37. Fernandes H, Cohen S, Bishayee S (2001) Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 276:5375–5383PubMedCrossRefGoogle Scholar
  38. Fukuoka M, Yano S, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246PubMedCrossRefGoogle Scholar
  39. Garrett TP, McKern NM, Lou M et al. (2003) The crystal structure of a truncated rbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495–505PubMedCrossRefGoogle Scholar
  40. Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176–13180PubMedCrossRefGoogle Scholar
  41. Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22:777–784PubMedCrossRefGoogle Scholar
  42. Gillison ML, Glisson BS, O’Leary E et al. (2006) Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J Clin Oncol 24(18S):5511 ­(meeting abstracts)Google Scholar
  43. Gleich LL, Gluckman JL, Armstrong S et al. (1998) Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 124:1097–1104PubMedGoogle Scholar
  44. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37–46PubMedCrossRefGoogle Scholar
  45. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584PubMedGoogle Scholar
  46. Graus-Porta D, Beerli RR, Daly JM (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655PubMedCrossRefGoogle Scholar
  47. Gschwind A, Hart S, Fischer OM et al. (2003) TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22:2411–2421PubMedCrossRefGoogle Scholar
  48. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361–370PubMedCrossRefGoogle Scholar
  49. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284:2–13PubMedCrossRefGoogle Scholar
  50. Hasegawa Y, Goto M, Hanai N et al. (2007) Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology 73:104–111PubMedCrossRefGoogle Scholar
  51. Heimberger AB, Crotty LE, Archer GE et al. (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9:4247–4254PubMedGoogle Scholar
  52. Heimberger AB, Hlatky R, Suki D et al. (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma mulepsorme patients. Clin Cancer Res 11:1462–1466PubMedCrossRefGoogle Scholar
  53. Herbst RS, Maddox AM, Rothenberg ML et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in ­non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815–3825PubMedCrossRefGoogle Scholar
  54. Herbst RS, Giaccone G, Schiller JH et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 22:785–794PubMedCrossRefGoogle Scholar
  55. Herbst RS, Arquette M, Shin DM et al. (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578–5587PubMedCrossRefGoogle Scholar
  56. Hsu SC, Hung MC (2007) Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 282:10432–10440PubMedCrossRefGoogle Scholar
  57. Izumi Y, Hirata M, Hasuwa H et al. (1998) A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17:7260–7272PubMedCrossRefGoogle Scholar
  58. Jackman M, Sequist LV, Cioffredi L et al. (2008) Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol 26(15S):8035 (meeting abstracts)Google Scholar
  59. Jaramillo ML, Leon Z, Grothe S et al. (2006) Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312:2778–2790PubMedCrossRefGoogle Scholar
  60. Ji H, Li D, Chen L et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485–495PubMedCrossRefGoogle Scholar
  61. Jimeno A, Messersmith WA, Hirsch FR et al. (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136PubMedCrossRefGoogle Scholar
  62. Khan EM, Heidinger JM, Levy M et al. (2006) Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 281:14486–14493PubMedCrossRefGoogle Scholar
  63. Kimura H, Sakai K, Arao T et al. (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98:1275–1280PubMedCrossRefGoogle Scholar
  64. Kobayashi S, Boggon TJ, Dayaram T et al. (2005) EGFR mMutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792PubMedCrossRefGoogle Scholar
  65. Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung ­cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRefGoogle Scholar
  66. Kwak EL, Sordella R, Bell DW et al. (2005) Irreversible inhibitors of the EGF receptor may ­circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665–7670PubMedCrossRefGoogle Scholar
  67. Lal A, Glazer CA, Martinson HM et al. (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335–3339PubMedGoogle Scholar
  68. Lammering G, Hewit TH, Valerie K et al. (2003) EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22:5545–5553PubMedCrossRefGoogle Scholar
  69. Learn CA, Hartzell TL, Wikstrand CJ et al. (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma mulepsorme. Clin Cancer Res 10:3216–3224PubMedCrossRefGoogle Scholar
  70. Lee JW, Soung YH, Kim SY et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879–2882PubMedCrossRefGoogle Scholar
  71. Lee TL, Yeh J, Van Waes C et al. (2006) Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5:8–19PubMedCrossRefGoogle Scholar
  72. Lee SC, Lopez-Albaitero A, Ferris RL (2009) Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. Curr Oncol Rep 11:156–162PubMedCrossRefGoogle Scholar
  73. Lenferink AE, Pinkas-Kramarski R, Van de Poll ML et al. (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385–3397PubMedCrossRefGoogle Scholar
  74. Lenz HJ, Van Cutsem E, Khambata-Ford et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and ­fluoropyrimidines. J Clin Oncol 24:4914–4921PubMedCrossRefGoogle Scholar
  75. Li B, Yuan M, Kim IA et al. (2004) Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23:4594–4602PubMedCrossRefGoogle Scholar
  76. Li S, Schmitz KR, Jeffrey PD et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311PubMedCrossRefGoogle Scholar
  77. Liao HJ, Carpenter G (2007) Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell 18:1064–1072PubMedCrossRefGoogle Scholar
  78. Lin SY, Makino K, Xia W et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802–808PubMedCrossRefGoogle Scholar
  79. Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120–1125PubMedGoogle Scholar
  80. Liu W, Innocenti F, Wu MH et al. (2005) A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65:46–53PubMedGoogle Scholar
  81. Liu G, Gurubhagavatula S, Zhou W et al. (2007) Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 8:129–138PubMedCrossRefGoogle Scholar
  82. Lo HW, Hsu SC, Ali-Seyed M et al. (2005a) Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7:575–589PubMedCrossRefGoogle Scholar
  83. Lo HW, Xia W, Wei Y et al. (2005b) Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65:338–348PubMedGoogle Scholar
  84. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. (2006) Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42:109–111PubMedCrossRefGoogle Scholar
  85. López-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133:1277–1281PubMedCrossRefGoogle Scholar
  86. López-Albaitero A, Lee SC, Morgan S et al. (2009) Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. doi:10.1007/s00262-009-0697-4PubMedGoogle Scholar
  87. Lu SL, (2006) Genes Dev 20:1331–1342Google Scholar
  88. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  89. Mandic R, Rodgarkia-Dara CJ, Zhu L et al. (2006) Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux®) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580:4793–4800PubMedCrossRefGoogle Scholar
  90. Mellinghoff IK, Wang MY, Vivanco I et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  91. Miettinen PJ, Berger JE, Meneses J et al. (1995) Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337–341PubMedCrossRefGoogle Scholar
  92. Mishima K, Johns TG, Luwor RB et al. (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the ­receptor. Cancer Res 61:5349–5354PubMedGoogle Scholar
  93. Modjtahedi H, Moscatello DK, Box G et al. (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105:273–280PubMedCrossRefGoogle Scholar
  94. Montagut C, Settleman J (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283(2):125–134PubMedCrossRefGoogle Scholar
  95. Montero AJ, Díaz-Montero CM, Mao L et al. (2006) Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 5:1494–1501PubMedCrossRefGoogle Scholar
  96. Morgillo F, Woo JK, Kim ES et al. (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66:10100–10111PubMedCrossRefGoogle Scholar
  97. Moroni M, Veronese S, Benvenuti S et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286PubMedCrossRefGoogle Scholar
  98. Moscatello DK, Montgomery RB, Sundareshan P et al. (1996) Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13:85–96PubMedGoogle Scholar
  99. Moscatello DK, Holgado-Madruga M, Emlet DR et al. (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273:200–206PubMedCrossRefGoogle Scholar
  100. Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62:3151–3158PubMedGoogle Scholar
  101. Nagane M, Levitzki A, Gazit A et al. (1998) Drug resistance of human glioblastoma cells ­conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724–5729PubMedCrossRefGoogle Scholar
  102. Naramura M, Gillies SD, Mendelsohn J et al. (1993) Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37:343–349PubMedCrossRefGoogle Scholar
  103. Nishikawa R, Ji XD, Harmon RC et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731PubMedCrossRefGoogle Scholar
  104. Olapade-Olaopa EO, Moscatello DK, MacKav EH et al. (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82:186–194PubMedCrossRefGoogle Scholar
  105. Overholser JP, Prewett MC, Hooper AT et al. (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74–82PubMedCrossRefGoogle Scholar
  106. Paez JG, Jänne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  107. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568PubMedCrossRefGoogle Scholar
  108. Pao W, Miller VA, Politi KA et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:225–235CrossRefGoogle Scholar
  109. Pedersen MW, Meltorn M, Damstrup L et al. (2001) The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12:745–760PubMedCrossRefGoogle Scholar
  110. Perera RM, Narita Y, Furnari FB et al. (2005) Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11:6390–6399PubMedCrossRefGoogle Scholar
  111. Pérez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 22:3238–3247PubMedCrossRefGoogle Scholar
  112. Pfister DG, Su YB, Kraus DH et al. (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072–1078PubMedCrossRefGoogle Scholar
  113. Prenzel N, Zwick E, Daub H et al. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884–888PubMedGoogle Scholar
  114. Psyrri A, Yu Z, Weinberger PM et al. (2005) Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11:5856–5862PubMedCrossRefGoogle Scholar
  115. Quesnelle KM, Boehm AL, Grandis JR (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102:311–319PubMedCrossRefGoogle Scholar
  116. Ratushny V, Astsaturov I, Burtness BA et al. (2009) Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21:1255–1268PubMedCrossRefGoogle Scholar
  117. Rich JN, Reardon DA, Peery T et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142PubMedCrossRefGoogle Scholar
  118. Riely GJ (2008) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 3:S146–S149PubMedCrossRefGoogle Scholar
  119. Riely GJ, Pao W, Pham D et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839–844PubMedCrossRefGoogle Scholar
  120. Rosenzweig SA, Oemar BS, Law NM et al. (1993) Insulin like growth factor 1 receptor signal transduction to the nucleus. Adv Exp Med Biol 343:159–168PubMedGoogle Scholar
  121. Salomon DS, Brandt R, Ciardiello F (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232PubMedCrossRefGoogle Scholar
  122. Sartore-Bianchi A, Moroni M, Veronese S et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238–3245PubMedCrossRefGoogle Scholar
  123. Sato JD, Kawamoto T, Le AD et al. (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511–529PubMedGoogle Scholar
  124. Schmittling RJ, Archer GE, Mitchell DA et al. (2008) Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339:74–81PubMedCrossRefGoogle Scholar
  125. Sequist LV, Bell DW, Lynch TJ et al. (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587–595PubMedCrossRefGoogle Scholar
  126. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRefGoogle Scholar
  127. Shinojima N, Tada K, Shiraishi S et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma mulepsorme. Cancer Res 63:6962–6970PubMedGoogle Scholar
  128. Shu X, Wu W, Mosteller RD et al. (2002) Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 22:7758–7768PubMedCrossRefGoogle Scholar
  129. Sigismund S, Woelk T, Puri C et al. (2005) Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102:2760–2765PubMedCrossRefGoogle Scholar
  130. Sigismund S, Argenzio E, Tosoni D et al. (2008) Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 15:209–219PubMedCrossRefGoogle Scholar
  131. Siu LL, Soulieres D, Chen EX et al. (2007) Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25:2178–2183PubMedCrossRefGoogle Scholar
  132. Sok JC, Coppelli FM, Thomas SM et al. (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073PubMedCrossRefGoogle Scholar
  133. Song L, Turkson J, Karras JG et al. (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22:4150–4165PubMedCrossRefGoogle Scholar
  134. Soulieres D, Senzer NN, Vokes EE et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or ­metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85PubMedCrossRefGoogle Scholar
  135. Srinivasan V, Sherman IW, O’Sullivan G (2000) Surgical management of intractable epistaxis: audit of results. J Laryngol Otol 114:697–700PubMedCrossRefGoogle Scholar
  136. Stachowiak MK, Maher PA, Stachowiak EK (2007) Integrative nuclear signaling in cell development−a role for FGF receptor-1. DNA Cell Biol 26:811–826PubMedCrossRefGoogle Scholar
  137. Sugawa N, Ekstrand AJ, James CD et al. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602–8606PubMedCrossRefGoogle Scholar
  138. Sunada H, Magun BE, Mendelsohn J et al. (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 83:3825–3829PubMedCrossRefGoogle Scholar
  139. Sunpaweravong P, Sunpaweravong S, Puttawilbul P et al. (2005) Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111–119PubMedCrossRefGoogle Scholar
  140. Tang C, Shou M, Mei Q et al. (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453–459PubMedGoogle Scholar
  141. Taylor RJ, Chan SL, Wood A et al. (2008) FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58:997–1006. doi:10.1007/s00262-008-0613-3PubMedCrossRefGoogle Scholar
  142. Temam S, Kawaguchi H, El-Naggar AK et al. (2007) Epidermal growth factor receptor copy ­number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164–2170PubMedCrossRefGoogle Scholar
  143. Trembath DG, Lal A, Kroll DJ et al. (2007) A novel small molecule that selectively inhibits ­glioblastoma cells expressing EGFRvIII. Mol Cancer 6:30PubMedCrossRefGoogle Scholar
  144. Van Cutsem E, Lang I, D’haens G et al. (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(15S):2 (meeting abstracts)Google Scholar
  145. Varchetta S, Gibelli N, Oliviero B et al. (2007) Elements related to heterogeneity of antibody-­dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991–11999PubMedCrossRefGoogle Scholar
  146. Wakatsuki S, Kurisaki T, Sehara-Fujisawa A (2004) Lipid rafts idenepsied as locations of ectodomain shedding mediated by Meltrin beta/ADAM19. J Neurochem 89:119–123PubMedCrossRefGoogle Scholar
  147. Ward WH, Cook PN, Slater AM et al. (1994) Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659–666PubMedCrossRefGoogle Scholar
  148. Waters MJ, Rowlinson SW, Clarkson RW et al. (1994) Signal transduction by the growth hormone receptor. Proc Soc Exp Biol Med 206:215–220Google Scholar
  149. Weinstein IB, Joe A (2008) Oncogene Addiction. Cancer Res 68:3077–3080PubMedCrossRefGoogle Scholar
  150. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947PubMedCrossRefGoogle Scholar
  151. Wheeler DL, Huang S, Kruser TJ et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27:3944–3956PubMedCrossRefGoogle Scholar
  152. Wirth LJ, Haddad RI, Lindeman NI et al. (2005) Phase I study of gefitinib plus celecoxib in ­recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23:6976–6981PubMedCrossRefGoogle Scholar
  153. Wong TW, Lee FY, Yu C et al. (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 12:6186–6193PubMedCrossRefGoogle Scholar
  154. Worden B, Yang XP, Lee TL et al. (2005) Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65:7071–7080PubMedCrossRefGoogle Scholar
  155. Wu AH, Xiao J, Anker L et al. (2006) Idenepsication of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76:23–30PubMedCrossRefGoogle Scholar
  156. Xia W, Wei Y, Du Y et al. (2008) Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48:610–617CrossRefGoogle Scholar
  157. Yano S, Wang W, Li Q et al. (2008) Haptocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68:9479–9487PubMedCrossRefGoogle Scholar
  158. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137PubMedCrossRefGoogle Scholar
  159. Yoshida T, Okamoto I, Okabe T et al. (2008) Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 122:1530–1538PubMedCrossRefGoogle Scholar
  160. Zhang W, Gordon M, Schultheis AM et al. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712–3718PubMedCrossRefGoogle Scholar
  161. Zhang W, Peyton M, Xie Y et al. (2009) Histone deacetylase inhibitor romidepsin enhances ­anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Throc Oncol 4:161–166CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of OtolaryngologyUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations